Anokion SA (including our wholly-owned subsidiaries Anokion US, Inc. and Kanyos Bio, Inc.) is focused on improving the treatment and outcomes of autoimmune disease. Our proprietary antigen-specific immune tolerance technology is designed to be both more effective and specific than the current standard of care.
Patients suffering from autoimmune diseases harbor immune cells that mistakenly recognize and attack the body’s o...
Anokion SA (including our wholly-owned subsidiaries Anokion US, Inc. and Kanyos Bio, Inc.) is focused on improving the treatment and outcomes of autoimmune disease. Our proprietary antigen-specific immune tolerance technology is designed to be both more effective and specific than the current standard of care.
Patients suffering from autoimmune diseases harbor immune cells that mistakenly recognize and attack the body’s own cells (self-proteins) as foreign entities. This can lead to tissue destruction, inflammation, and any number of serious complications. The cells that cause these erroneous attacks are known as autoreactive cells.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.